文献(1-100)

1. McMurray JJ, Adamopoulos S, Anker SD, et al. ESC guidelines for the diagnosis and treatment of acute and chronic heart failure

2012: The Task Force for the Diagnosis and Treatment of Acute and Chronic Heart Failure 2012 of the European Society of

Cardiology. Developed in collaboration with the Heart Failure Association (HFA) of the ESC. Eur J Heart Fail 2012; 14: 803-869. PMID:

22828712

2. Guidelines for the evaluation and management of heart failure. Report of the American College of Cardiology/American Heart

Association Task Force on Practice Guidelines (Committee on Evaluation and Management of Heart Failure). J Am Coll Cardiol 1995;

26: 1376-1398. PMID: 7594057

3. Hunt SA, Baker DW, Chin MH, et al. ACC/AHA Guidelines for the Evaluation and Management of Chronic Heart Failure in the Adult:

Executive Summary A Report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines

(Committee to Revise the 1995 Guidelines for the Evaluation and Management of Heart Failure): Developed in Collaboration With the

International Society for Heart and Lung Transplantation; Endorsed by the Heart Failure Society of America. Circulation 2001; 104:

2996-3007. PMID: 11739319

4. Hunt SA, Abraham WT, Chin MH, et al. ACC/AHA 2005 Guideline Update for the Diagnosis and Management of Chronic Heart Failure

in the Adult: a report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines (Writing

Committee to Update the 2001 Guidelines for the Evaluation and Management of Heart Failure): developed in collaboration with the

American College of Chest Physicians and the International Society for Heart and Lung Transplantation: endorsed by the Heart

Rhythm Society. Circulation 2005; 112: e154-e235. PMID: 16160202

5. Hunt SA, Abraham WT, Chin MH, et al. 2009 focused update incorporated into the ACC/AHA 2005 Guidelines for the Diagnosis and

Management of Heart Failure in Adults: a report of the American College of Cardiology Foundation/American Heart Association Task

Force on Practice Guidelines: developed in collaboration with the International Society for Heart and Lung Transplantation. Circulation

2009; 119: e391-e479. PMID: 19324966

6. Dickstein K, Cohen-Solal A, Filippatos G, et al. ESC Committee for Practice Guidelines (CPG). ESC guidelines for the diagnosis and

treatment of acute and chronic heart failure 2008: the Task Force for the diagnosis and treatment of acute and chronic heart failure

2008 of the European Society of Cardiology. Developed in collaboration with the Heart Failure Association of the ESC (HFA) and

endorsed by the European Society of Intensive Care Medicine (ESICM). Eur J Heart Fail 2008; 10: 933-989. PMID: 18826876

7. Yancy CW, Jessup M, Bozkurt B, et al. 2013 ACCF/AHA guideline for the management of heart failure: a report of the American

College of Cardiology Foundation/American Heart Association Task Force on practice guidelines. Circulation 2013; 128: e240-e327.

PMID: 23741058

8. Yancy CW, Jessup M, Bozkurt B, et al. 2017 ACC/AHA/HFSA Focused Update of the 2013 ACCF/AHA Guideline for the

Management of Heart Failure: A Report of the American College of Cardiology/American Heart Association Task Force on Clinical

Practice Guidelines and the Heart Failure Society of America. Circulation 2017; 136: e137-e161. PMID: 28455343

9. Guidelines for the diagnosis of heart failure. The Task Force on Heart Failure of the European Society of Cardiology. Eur Heart J 1995;

16: 741-751. PMID: 7588917

10. The treatment of heart failure. Task Force of the Working Group on Heart Failure of the European Society of Cardiology. Eur Heart

J 1997; 18: 736-753. PMID: 9152644

11. Remme WJ, Swedberg K. Task Force for the Diagnosis and Treatment of Chronic Heart Failure, European Society of Cardiology.

Guidelines for the diagnosis and treatment of chronic heart failure. Eur Heart J 2001; 22: 1527-1560. PMID: 11492984

12. Swedberg K, Cleland J, Dargie H, et al. Guidelines for the diagnosis and treatment of chronic heart failure: executive summary

(update 2005): The Task Force for the Diagnosis and Treatment of Chronic Heart Failure of the European Society of Cardiology.

Eur Heart J 2005; 26: 1115-1140. PMID: 15901669

13. Nieminen MS, Böhm M, Cowie MR, et al. ESC Committe for Practice Guideline (CPG). Executive summary of the guidelines on

the diagnosis and treatment of acute heart failure: the Task Force on Acute Heart Failure of the European Society of Cardiology.

Eur Heart J 2005; 26: 384-416. PMID: 15681577

14. Ponikowski P, Voors AA, Anker SD, et al. Authors/Task Force Members. 2016 ESC Guidelines for the diagnosis and treatment

of acute and chronic heart failure: The Task Force for the diagnosis and treatment of acute and chronic heart failure of the European

Society of Cardiology (ESC)Developed with the special contribution of the Heart Failure Association (HFA) of the ESC. Eur Heart J

2016; 37: 2129-2200. PMID: 27206819

15. Minds診療ガイドライン選定部会監修．福井次矢，吉田雅博，山口直人編．Minds診療ガイドライン作成の手引き 2007．医学書院 2007.

16. Ponikowski P, Voors AA, Anker SD, et al. Authors/Task Force Members. 2016 ESC Guidelines for the diagnosis and treatment of

acute and chronic heart failure: The Task Force for the diagnosis and treatment of acute and chronic heart failure of the European

Society of Cardiology (ESC). Developed with the special contribution of the Heart Failure Association (HFA) of the ESC. Eur J

Heart Fail 2016; 18: 891-975. PMID: 27207191

17. Owan TE, Hodge DO, Herges RM, et al. Trends in prevalence and outcome of heart failure with preserved ejection fraction. N Engl

J Med 2006; 355: 251-259. PMID: 16855265

18. Lee DS, Gona P, Vasan RS, et al. Relation of disease pathogenesis and risk factors to heart failure with preserved or reduced

ejection fraction: insights from the framingham heart study of the national heart, lung, and blood institute. Circulation 2009; 119:

3070-3077. PMID: 19506115

19. Punnoose LR, Givertz MM, Lewis EF, et al. Heart failure with recovered ejection fraction: a distinct clinical entity. J Card Fail 2011;

17: 527-532. PMID: 21703523

20. 厚生労働省．脳卒中、心臓病その他の循環器病に係る診療提供体制の在り方に関する検討会．脳卒中、心臓病その他の循環器病に係る

診療提供体制の在り方について（平成29年7月）． http://www.mhlw.go.jp/file/05-Shingikai-10901000-Kenkoukyoku-Soumuka/

0000173149.pdf

21. Forrester JS, Diamond G, Chatterjee K, et al. Medical therapy of acute myocardial infarction by application of hemodynamic subsets

(second of two parts). N Engl J Med 1976; 295: 1404-1413. PMID: 790194

22. Nohria A, Tsang SW, Fang JC, et al. Clinical assessment identifies hemodynamic profiles that predict outcomes in patients admitted

with heart failure. J Am Coll Cardiol 2003; 41: 1797-1804. PMID: 12767667

23. 厚生労働省．平成26年（2014）人口動態統計（確定数）の概況．http://www.mhlw.go.jp/toukei/saikin/hw/jinkou/kakutei14/index.html

24. 日本循環器学会．循環器疾患診療実態調査報告書（2016年度実施・公表）．http://www.j-circ.or.jp/jittai_chosa/jittai_chosa2015web.pdf

25. Okura Y, Ramadan MM, Ohno Y, et al. Impending epidemic: future projection of heart failure in Japan to the year 2055. Circ J 2008;

72: 489-491. PMID: 18296852

26. American Heart Association: Heart Disease and Stroke Statistics ̶2005 Update. Dallas, Tex; American Heart Association; 2005.

27. Vasan RS, Larson MG, Benjamin EJ, et al. Congestive heart failure in subjects with normal versus reduced left ventricular ejection

fraction: prevalence and mortality in a population-based cohort. J Am Coll Cardiol 1999; 33: 1948-1955. PMID: 10362198

28. Tsutsui H, Tsuchihashi-Makaya M, Kinugawa S, et al. JCARE-CARD Investigators. Clinical characteristics and outcome of

hospitalized patients with heart failure in Japan. Circ J 2006; 70: 1617-1623. PMID: 17127810

29. Shiba N, Watanabe J, Shinozaki T, et al. CHART Investigators. Analysis of chronic heart failure registry in the Tohoku district: third

year follow-up. Circ J 2004; 68: 427-434. PMID: 15118283

30. Shiba N, Nochioka K, Miura M, et al. CHART-2 Investigators. Trend of westernization of etiology and clinical characteristics of heart

failure patients in Japan--first report from the CHART-2 study. Circ J 2011; 75: 823-833. PMID: 21436596

31. Ushigome R, Sakata Y, Nochioka K, et al. CHART-2 Investigators. Temporal trends in clinical characteristics, management and

prognosis of patients with symptomatic heart failure in Japan -- report from the CHART Studies. Circ J 2015; 79: 2396-2407. PMID:

26356834

32 Tsuchihashi-Makaya M, Hamaguchi S, Kinugawa S, et al. JCARECARD Investigators. Characteristics and outcomes of hospitalized

patients with heart failure and reduced vs preserved ejection fraction. Report from the Japanese Cardiac Registry of Heart Failure in

Cardiology (JCARE-CARD). Circ J 2009; 73: 1893-1900. PMID: 19644216

33. Berry C. Meta-analysis Global Group in Chronic Heart Failure (MAGGIC). The survival of patients with heart failure with preserved

or reduced left ventricular ejection fraction: an individual patient data meta-analysis. Eur Heart J 2012; 33: 1750-1757. PMID:

21821849

34. Tsuji K, Sakata Y, Nochioka K, et al. CHART-2 Investigators. Characterization of heart failure patients with mid-range left ventricular

ejection fraction-a report from the CHART-2 Study. Eur J Heart Fail 2017; 19: 1258-1269. PMID: 28370829

35. Kawashiro N, Kasanuki H, Ogawa H, et al. Heart Institute of Japan--Department of Cardiology (HIJC) Investigators. Clinical

characteristics and outcome of hospitalized patients with congestive heart failure: results of the HIJC-HF registry. Circ J 2008; 72:

2015-2020. PMID: 18931450

36. Sato N, Kajimoto K, Keida T, et al. ATTEND Investigators. Clinical features and outcome in hospitalized heart failure in Japan (from

the ATTEND Registry). Circ J 2013; 77: 944-951. PMID: 23502987

37. Adams KF, Fonarow GC, Emerman CL, et al. ADHERE Scientific Advisory Committee and Investigators. Characteristics and

outcomes of patients hospitalized for heart failure in the United States: rationale, design, and preliminary observations from the first

100,000 cases in the Acute Decompensated Heart Failure National Registry (ADHERE). Am Heart J 2005; 149: 209-216. PMID:

15846257

38. Nieminen MS, Brutsaert D, Dickstein K, et al. EuroHeart Survey Investigators. EuroHeart Failure Survey II (EHFS II): a survey on

hospitalized acute heart failure patients: description of population. Eur Heart J 2006; 27: 2725-2736. PMID: 17000631

39. Ho KK, Anderson KM, Kannel WB, et al. Survival after the onset of congestive heart failure in Framingham Heart Study subjects.

Circulation 1993; 88: 107-115. PMID: 8319323

40. Lloyd-Jones DM, Larson MG, Leip EP, et al. Framingham Heart Study. Lifetime risk for developing congestive heart failure: the

Framingham Heart Study. Circulation 2002; 106: 3068-3072. PMID: 12473553

41. Bleumink GS, Knetsch AM, Sturkenboom MC, et al. Quantifying the heart failure epidemic: prevalence, incidence rate, lifetime risk

and prognosis of heart failure The Rotterdam Study. Eur Heart J 2004; 25: 1614-1619. PMID: 15351160

42. Sakata Y, Miyata S, Nochioka K, et al. Gender differences in clinical characteristics, treatment and long-term outcome in patients

with stage C/D heart failure in Japan. Report from the CHART-2 study. Circ J 2014; 78: 428-435. PMID: 24317114

43. 日本心不全学会予防委員会．血中BNP やNT-proBNP値を用いた心不全診療の留意点について．

http://www.asas.or.jp/jhfs/topics/bnp201300403.html

44. McKee PA, Castelli WP, McNamara PM, et al. The natural history of congestive heart failure: the Framingham study. N Engl J Med

1971; 285: 1441-1446. PMID: 5122894

45. Cohn JN, Levine TB, Olivari MT, et al. Plasma norepinephrine as a guide to prognosis in patients with chronic congestive heart failure.

N Engl J Med 1984; 311: 819-823. PMID: 6382011

46. Kawaguchi H, Kitabatake A. Renin-angiotensin system in failing heart. J Mol Cell Cardiol 1995; 27: 201-209. PMID: 7760344

47. Iwai N, Shimoike H, Kinoshita M. Cardiac renin-angiotensin system in the hypertrophied heart. Circulation 1995; 92: 2690-2696.

PMID: 7586374

48. Mizuno Y, Yoshimura M, Yasue H, et al. Aldosterone production is activated in failing ventricle in humans. Circulation 2001; 103: 72-

77. PMID: 11136688

49. Young M, Fullerton M, Dilley R, et al. Mineralocorticoids, hypertension, and cardiac fibrosis. J Clin Invest 1994; 93: 2578-2583.

PMID:

8200995

50. Struthers AD, MacDonald TM. Review of aldosterone- and angiotensin II-induced target organ damage and prevention. Cardiovasc

Res

2004; 61: 663-670. PMID: 14985063

51. Yamamuro M, Yoshimura M, Nakayama M, et al. Direct effects of aldosterone on cardiomyocytes in the presence of normal and

elevated extracellular sodium. Endocrinology 2006; 147: 1314-1321. PMID: 16373419

52. Sudoh T, Kangawa K, Minamino N, et al. A new natriuretic peptide in porcine brain. Nature 1988; 332: 78-81. PMID: 2964562

53. Mukoyama M, Nakao K, Hosoda K, et al. Brain natriuretic peptide as a novel cardiac hormone in humans. Evidence for an exquisite

dual natriuretic peptide system, atrial natriuretic peptide and brain natriuretic peptide. J Clin Invest 1991; 87: 1402-1412. PMID:

1849149

54. Nakao K, Ogawa Y, Suga S, et al. Molecular biology and biochemistry of the natriuretic peptide system. I: Natriuretic peptides. J

Hypertens 1992; 10: 907-912. PMID: 1328371

55. Yoshimura M, Yasue H, Okumura K, et al. Different secretion patterns of atrial natriuretic peptide and brain natriuretic peptide in

patients with congestive heart failure. Circulation 1993; 87: 464-469. PMID: 8425293

56. Yasue H, Yoshimura M, Sumida H, et al. Localization and mechanism of secretion of B-type natriuretic peptide in comparison with

those of A-type natriuretic peptide in normal subjects and patients with heart failure. Circulation 1994; 90: 195-203. PMID: 8025996

57. Maisel AS, Nakao K, Ponikowski P, et al. Japanese-Western consensus meeting on biomarkers. Int Heart J 2011; 52: 253-265.

PMID: 22008432

58. Yamamoto K, Burnett JC, Jougasaki M, et al. Superiority of brain natriuretic peptide as a hormonal marker of ventricular systolic and

diastolic dysfunction and ventricular hypertrophy. Hypertension 1996; 28: 988-994. PMID: 8952587

59. Tsutamoto T, Wada A, Maeda K, et al. Attenuation of compensation of endogenous cardiac natriuretic peptide system in chronic

heart failure: prognostic role of plasma brain natriuretic peptide concentration in patients with chronic symptomatic left ventricular

dysfunction. Circulation 1997; 96: 509-516. PMID: 9244219

60. Omland T, Persson A, Ng L, et al. N-terminal pro-B-type natriuretic peptide and long-term mortality in acute coronary syndromes.

Circulation 2002; 106: 2913-2918. PMID: 12460871

61. Anand IS, Fisher LD, Chiang YT, et al. Val-HeFT Investigators. Changes in brain natriuretic peptide and norepinephrine over time

and mortality and morbidity in the Valsartan Heart Failure Trial (Val- HeFT). Circulation 2003; 107: 1278-1283. PMID: 12628948

62. Suzuki S, Yoshimura M, Nakayama M, et al. Plasma level of B-type natriuretic peptide as a prognostic marker after acute

myocardial

infarction: a long-term follow-up analysis. Circulation 2004; 110: 1387-1391. PMID: 15353502

63. Price JF, Thomas AK, Grenier M, et al. B-type natriuretic peptide predicts adverse cardiovascular events in pediatric outpatients with

chronic left ventricular systolic dysfunction. Circulation 2006; 114: 1063-1069. PMID: 16940194

64. Nishii M, Inomata T, Takehana H, et al. Prognostic utility of B-type natriuretic peptide assessment in stable low-risk outpatients with

nonischemic cardiomyopathy after decompensated heart failure. J Am Coll Cardiol 2008; 51: 2329-2335. PMID: 18549918

65. Seino Y, Ogawa A, Yamashita T, et al. Application of NT-proBNP and BNP measurements in cardiac care: a more discerning marker

for the detection and evaluation of heart failure. Eur J Heart Fail 2004; 6: 295-300. PMID: 14987579

66. Kawai M, Yoshimura M, Harada M, et al. Determination of the B-type natriuretic peptide level as a criterion for abnormalities in

Japanese individuals in routine clinical practice: the J-ABS Multi-Center Study (Japan Abnormal BNP Standard). Intern Med 2013; 52:

171- 177. PMID: 23318845

67. Sato Y, Yamada T, Taniguchi R, et al. Persistently increased serum concentrations of cardiac troponin t in patients with idiopathic

dilated cardiomyopathy are predictive of adverse outcomes. Circulation 2001; 103: 369-374. PMID: 11157687

68. Ishii J, Cui W, Kitagawa F, et al. Prognostic value of combination of cardiac troponin T and B-type natriuretic peptide after initiation of

treatment in patients with chronic heart failure. Clin Chem 2003; 49: 2020-2026. PMID: 14633873

69. Keller T, Zeller T, Peetz D, et al. Sensitive troponin I assay in early diagnosis of acute myocardial infarction. N Engl J Med 2009; 361:

868-877. PMID: 19710485

70. Reichlin T, Hochholzer W, Bassetti S, et al. Early diagnosis of myocardial infarction with sensitive cardiac troponin assays. N Engl J

Med 2009; 361: 858-867. PMID: 19710484

71. Latini R, Masson S, Anand IS, et al. Val-HeFT Investigators. Prognostic value of very low plasma concentrations of troponin T in

patients with stable chronic heart failure. Circulation 2007; 116: 1242-1249. PMID: 17698733

72. Tsutamoto T, Kawahara C, Nishiyama K, et al. Prognostic role of highly sensitive cardiac troponin I in patients with systolic heart

failure. Am Heart J 2010; 159: 63-67. PMID: 20102868

73. Levine B, Kalman J, Mayer L, et al. Elevated circulating levels of tumor necrosis factor in severe chronic heart failure. N Engl J Med

1990; 323: 236-241. PMID: 2195340

74. Ferrari R, Bachetti T, Confortini R, et al. Tumor necrosis factor soluble receptors in patients with various degrees of congestive heart

failure. Circulation 1995; 92: 1479-1486. PMID: 7664430

75. Tsutamoto T, Hisanaga T, Wada A, et al. Interleukin-6 spillover in the peripheral circulation increases with the severity of heart failure,

and the high plasma level of interleukin-6 is an important prognostic predictor in patients with congestive heart failure. J Am Coll

Cardiol 1998; 31: 391-398. PMID: 9462584

76. Anand IS, Latini R, Florea VG, et al. Val-HeFT Investigators. C-reactive protein in heart failure: prognostic value and the effect of

valsar

tan. Circulation 2005; 112: 1428-1434. PMID: 16129801

77. Pascual-Figal DA, Ordoñez-Llanos J, Tornel PL, et al. MUSIC Investigators. Soluble ST2 for predicting sudden cardiac death in

patients with chronic heart failure and left ventricular systolic dysfunction. J Am Coll Cardiol 2009; 54: 2174-2179. PMID: 19942089

78. Tsutamoto T, Wada A, Matsumoto T, et al. Relationship between tumor necrosis factor-alpha production and oxidative stress in the

failing hearts of patients with dilated cardiomyopathy. J Am Coll Cardiol 2001; 37: 2086-2092. PMID: 11419892

79. Tsutsui T, Tsutamoto T, Wada A, et al. Plasma oxidized low-density lipoprotein as a prognostic predictor in patients with chronic

congestive heart failure. J Am Coll Cardiol 2002; 39: 957-962. PMID: 11897436

80. Watanabe E, Matsuda N, Shiga T, et al. Significance of 8-hydroxy- 2’-deoxyguanosine levels in patients with idiopathic dilated

cardiomyopathy. J Card Fail 2006; 12: 527-532. PMID: 16952786

81. Anker SD, Doehner W, Rauchhaus M, et al. Uric acid and survival in chronic heart failure: validation and application in metabolic,

functional, and hemodynamic staging. Circulation 2003; 107: 1991-1997. PMID: 12707250

82. Sakai H, Tsutamoto T, Tsutsui T, et al. Serum level of uric acid, partly secreted from the failing heart, is a prognostic marker in

patients with congestive heart failure. Circ J 2006; 70: 1006-1011. PMID: 16864933

83. Kittleson MM, Bead V, Fradley M, et al. Elevated uric acid levels predict allograft vasculopathy in cardiac transplant recipients. J

Heart Lung Transplant 2007; 26: 498-503. PMID: 17449420

84. Hamaguchi S, Furumoto T, Tsuchihashi-Makaya M, et al. JCARECARD Investigators. Hyperuricemia predicts adverse outcomes in

patients with heart failure. Int J Cardiol 2011; 151: 143-147. PMID: 20542341

85. Neuhold S, Huelsmann M, Strunk G, et al. Comparison of copeptin, B-type natriuretic peptide, and amino-terminal pro-B-type

natriuretic peptide in patients with chronic heart failure: prediction of death at different stages of the disease. J Am Coll Cardiol 2008;

52: 266-272. PMID: 18634981

86. Kistorp C, Faber J, Galatius S, et al. Plasma adiponectin, body mass index, and mortality in patients with chronic heart failure.

Circulation 2005; 112: 1756-1762. PMID: 16157772

87. George J, Patal S, Wexler D, et al. Circulating adiponectin concentrations in patients with congestive heart failure. Heart 2006; 92:

1420- 1424. PMID: 16621874

88. Tsutamoto T, Tanaka T, Sakai H, et al. Total and high molecular weight adiponectin, haemodynamics, and mortality in patients with

chronic heart failure. Eur Heart J 2007; 28: 1723-1730. PMID: 17507366

89. Yanagisawa M, Kurihara H, Kimura S, et al. A novel potent vasoconstrictor peptide produced by vascular endothelial cells. Nature

1988; 332: 411-415. PMID: 2451132

90. Tsutamoto T, Hisanaga T, Fukai D, et al. Prognostic value of plasma soluble intercellular adhesion molecule-1 and endothelin-1

concentration in patients with chronic congestive heart failure. Am J Cardiol 1995; 76: 803-808. PMID: 7572659

91. Van Beneden R, Gurné O, Selvais PL, et al. Superiority of big endothelin- 1 and endothelin-1 over natriuretic peptides in predicting

survival in severe congestive heart failure: a 7-year follow-up study. J Card Fail 2004; 10: 490-495. PMID: 15599839

92. Nagaya N, Satoh T, Nishikimi T, et al. Hemodynamic, renal, and hormonal effects of adrenomedullin infusion in patients with

congestive heart failure. Circulation 2000; 101: 498-503. PMID: 10662746

93. Wiener-Kronish JP, Matthay MA, Callen PW, et al. Relationship of pleural effusions to pulmonary hemodynamics in patients with

congestive heart failure. Am Rev Respir Dis 1985; 132: 1253-1256. PMID: 3907444

94. Gehlbach BK, Geppert E. The pulmonary manifestations of left heart failure. Chest 2004; 125: 669-682. PMID: 14769751

95. Daimon M, Watanabe H, Abe Y, et al. JAMP Study Investigators. Normal values of echocardiographic parameters in relation to age in

a healthy Japanese population: the JAMP study. Circ J 2008; 72: 1859- 1866. PMID: 18827372

96. Lang RM, Badano LP, Mor-Avi V, et al. Recommendations for cardiac chamber quantification by echocardiography in adults: an

update from the American Society of Echocardiography and the European Association of Cardiovascular Imaging. J Am Soc

Echocardiogr 2015; 28: 1-39.e14. PMID: 25559473

97. Voigt JU, Pedrizzetti G, Lysyansky P, et al. Definitions for a common standard for 2D speckle tracking echocardiography:

consensus

document of the EACVI/ASE/Industry Task Force to standardize deformation imaging. J Am Soc Echocardiogr 2015; 28: 183-193.

PMID: 25623220

98. Ommen SR, Nishimura RA, Appleton CP, et al. Clinical utility of Doppler echocardiography and tissue Doppler imaging in the

estimation of left ventricular filling pressures: A comparative simultaneous Doppler-catheterization study. Circulation 2000; 102: 1788-

1794. PMID: 11023933

99. Geske JB, Sorajja P, Nishimura RA, et al. Evaluation of left ventricular filling pressures by Doppler echocardiography in patients with

hypertrophic cardiomyopathy: correlation with direct left atrial pressure measurement at cardiac catheterization. Circulation 2007;

116:

2702- 2708. PMID: 18025528

100. Pritchett AM, Mahoney DW, Jacobsen SJ, et al. Diastolic dysfunction and left atrial volume: a population-based study. J Am Coll

Cardiol 2005; 45: 87-92. PMID: 15629380